Aktienanalyse zu LifeVantage Corp (LFVN)

KI-Analyse of LifeVantage Corp (LFVN)

Halten

LifeVantage Corp (LFVN) is currently not a strong buy due to its recent performance and financial indicators. The current price is $5.87, which is significantly below its 52-week high of $11.71, indicating potential for recovery but also substantial risk. The RSI is at 43.11, suggesting it is not yet oversold, and the forward P/E ratio is high at 37.45, reflecting concerns about future earnings growth. Additionally, the company reported a 23.1% revenue decline in Q4 2026, which raises red flags about its financial health. The main risk is the high short interest at 28.46%, indicating skepticism from investors about its recovery prospects. Overall, while there may be some upside potential, the current indicators suggest a cautious approach is warranted.

Bewertungskennzahlen

Das aktuelle erwartete KGV von LifeVantage Corp (LFVN) beträgt 37.45, verglichen mit dem 5-Jahres-Durchschnitt von 15.25.

Erwartetes KGV

Überbewertet

5J-Durchschnitt P/E

15.25

Aktuelles P/E

37.45

Überbewertet

27.08

Unterbewertet

3.42

Erwartetes EV/EBITDA

Fair bewertet

5J-Durchschnitt EV/EBITDA

5.38

Aktuelles EV/EBITDA

7.49

Überbewertet

8.08

Unterbewertet

2.69

Erwartetes KUV

Fair bewertet

5J-Durchschnitt P/S

0.44

Aktuelles P/S

0.45

Überbewertet

0.64

Unterbewertet

0.24

Alphio-AI-Kursszenarien für LFVN

Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.

B

Bullisch

Bullisch · 25%LFVN

$16.23

Szenariopreis

B

Basis

Basis · 50%LFVN

$13.81

Szenariopreis

B

Bärisch

Bärisch · 25%LFVN

$12.31

Szenariopreis

LFVN FAQ – beantwortet von Alphio AI

LifeVantage Corporation is an activation company, which is engage in the identification, research, development, formulation and sale of advanced nutrigenomic activators, dietary supplements, weight management products, pre- and pro-biotics, skin and hair care products, and nootropics. The Company’s line of scientifically validated activators includes the flagship Protandim family of products, TrueScience Liquid Collagen, the newest MindBody GLP-1 System, Activation-supporting nutrients such as Omega, D3+, and the Rise AM & Reset PM System , as well as AXIO nootropic energy drink mixes, the full TrueScience line of skin and hair care products, and Petandim, a pet supplement formulated to combat oxidative stress in dogs. It sells its products in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand and Singapore. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

LifeVantage Corp (LFVN) is currently not a strong buy due to its recent performance and financial indicators. The current price is $5.87, which is significantly below its 52-week high of $11.71, indicating potential for recovery but also substantial risk. The RSI is at 43.11, suggesting it is not yet oversold, and the forward P/E ratio is high at 37.45, reflecting concerns about future earnings growth. Additionally, the company reported a 23.1% revenue decline in Q4 2026, which raises red flags about its financial health. The main risk is the high short interest at 28.46%, indicating skepticism from investors about its recovery prospects. Overall, while there may be some upside potential, the current indicators suggest a cautious approach is warranted.